Century Therapeutics (IPSC) Free Cash Flow (2020 - 2026)

Century Therapeutics (IPSC) has reported Free Cash Flow for 7 consecutive years, with -$25.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 26.36% year-over-year to -$25.8 million; the TTM figure through Mar 2026 stood at -$95.5 million (up 17.14% YoY), while the FY2025 annual figure was -$104.7 million, up 5.02% from the prior year.
• Free Cash Flow fell to -$25.8 million in Q1 2026 per IPSC's latest filing, from -$16.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $82.7 million in Q1 2022 and bottomed at -$36.0 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$19.5 million across 5 years, with a median of -$27.2 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 443.62% — and 2023, when it plunged 2121.22%.
• Century Therapeutics' Free Cash Flow stood at -$1.2 million in 2022, then slumped by 2121.22% to -$27.2 million in 2023, then advanced by 10.98% to -$24.2 million in 2024, then soared by 34.1% to -$16.0 million in 2025, then plunged by 61.92% to -$25.8 million in 2026.
• Business Quant data shows IPSC's Free Cash Flow at -$25.8 million in Q1 2026, -$16.0 million in Q4 2025, and -$25.8 million in Q3 2025.